CORT - Corcept Therapeutics Incorporated
| Previous Close | 13.66 |
| Open | 13.98 |
| Bid | 14.15 x 800 |
| Ask | 14.17 x 900 |
| Day's Range | 13.50 - 14.37 |
| 52 Week Range | 9.55 - 17.48 |
| Volume | 452,059 |
| Avg. Volume | 896,086 |
| Market Cap | 1.622B |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | 19.96 |
| EPS (TTM) | 0.71 |
| Earnings Date | May 06, 2020 - May 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- Zacks
Corcept Therapeutics (CORT) Meets Q4 Earnings Estimates
Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -0.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update
MENLO PARK, Calif., Feb. 20, 2020 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat.
- Zacks
Why Corcept (CORT) Could Beat Earnings Estimates Again
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks
What's in Store for Corcept (CORT) This Earnings Season?
During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.
- Zacks
Corcept Therapeutics (CORT) to Report Q4 Results: What Awaits?
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Corcept Therapeutics to Announce Audited Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Feb. 13, 2020 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its audited 2019 fourth quarter and full-year financial.
- Investor's Business Daily
Biotech Stocks Ran Up In 2019 — Who's Leading The Pack For 2020?
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
- GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2019 Preliminary Selected Financial Results; Provides 2020 Revenue Guidance
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the stress hormone cortisol, today reported preliminary fourth quarter revenue of $87.9 million, compared to $66.8 million in the fourth quarter of 2018. Preliminary 2019 revenue was $306.5 million, an increase of 22 percent from 2018.
- Simply Wall St.
How Corcept Therapeutics Incorporated (NASDAQ:CORT) Can Impact Your Portfolio Volatility
If you own shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) then it's worth thinking about how it contributes...
- Zacks
Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.
- Zacks
Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.
- Zacks
Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study
Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.
- Zacks
Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA
The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).
- Zacks
Catalyst Gives Preliminary Firdapse Estimates & Other Updates
Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.
- Simply Wall St.
Read This Before Selling Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- Insider Monkey
Hedge Funds Are Buying Corcept Therapeutics Incorporated (CORT)
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
- Zacks
Why Is Corcept (CORT) Down 8.9% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Why Corcept Therapeutics Incorporated's (NASDAQ:CORT) High P/E Ratio Isn't Necessarily A Bad Thing
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll apply a basic...
- Thomson Reuters StreetEvents
Edited Transcript of CORT earnings conference call or presentation 7-Nov-19 10:00pm GMT
Q3 2019 Corcept Therapeutics Inc Earnings Call
- Zacks
Can The Uptrend Continue for Corcept Therapeutics?
As of late, it has definitely been a great time to be an investor Corcept Therapeutics.
- Zacks
Options Traders Expect Huge Moves in Corcept (CORT) Stock
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.
- Zacks
Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales
Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.
- Zacks
Corcept Therapeutics (CORT) Surpasses Q3 Earnings and Revenue Estimates
Corcept (CORT) delivered earnings and revenue surprises of 15.79% and 5.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
